Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan

Taku Aoki, Norihiro Kokudo, Izumi Komoto, Kyoichi Takaori, Wataru Kimura, Keiji Sano, Takeshi Takamoto, Takuya Hashimoto, Takuji Okusaka, Chigusa Morizane, Tetsuhide Ito, Masayuki Imamura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. In Western countries, streptozocin (STZ) has been established as a first-line anticancer drug for unresectable NET; however, STZ cannot be used in daily practice in Japan. The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. Methods: A retrospective multi-center survey was conducted. Five institutions with experience performing STZ chemotherapy participated in the study. The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. Results: Fifty-four patients were enrolled. The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. STZ monotherapy was used in one-fourth of the patients. The median progression-free and overall survival periods were 11.8 and 38.7 months, respectively, and sustained stable disease was obtained in some selected patients. The adverse events profile was mild and tolerable. Conclusions: Our survey showed the clinical benefit and safety of STZ therapy for Japanese patients with unresectable NET. Therefore, we recommend that STZ, which is the only cytotoxic agent available against NET, should be used in daily practice in Japan.

Original languageEnglish
Pages (from-to)769-775
Number of pages7
JournalJournal of gastroenterology
Volume50
Issue number7
DOIs
Publication statusPublished - Oct 28 2015

Fingerprint

Neuroendocrine Tumors
Streptozocin
Japan
Drug Therapy
Neoplasm Metastasis
Liver
Surveys and Questionnaires
Safety
Cytotoxins
Intravenous Administration
Antineoplastic Agents
Disease-Free Survival
Demography

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors : an analysis of a multi-center survey in Japan. / Aoki, Taku; Kokudo, Norihiro; Komoto, Izumi; Takaori, Kyoichi; Kimura, Wataru; Sano, Keiji; Takamoto, Takeshi; Hashimoto, Takuya; Okusaka, Takuji; Morizane, Chigusa; Ito, Tetsuhide; Imamura, Masayuki.

In: Journal of gastroenterology, Vol. 50, No. 7, 28.10.2015, p. 769-775.

Research output: Contribution to journalArticle

Aoki, T, Kokudo, N, Komoto, I, Takaori, K, Kimura, W, Sano, K, Takamoto, T, Hashimoto, T, Okusaka, T, Morizane, C, Ito, T & Imamura, M 2015, 'Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan', Journal of gastroenterology, vol. 50, no. 7, pp. 769-775. https://doi.org/10.1007/s00535-014-1006-3
Aoki, Taku ; Kokudo, Norihiro ; Komoto, Izumi ; Takaori, Kyoichi ; Kimura, Wataru ; Sano, Keiji ; Takamoto, Takeshi ; Hashimoto, Takuya ; Okusaka, Takuji ; Morizane, Chigusa ; Ito, Tetsuhide ; Imamura, Masayuki. / Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors : an analysis of a multi-center survey in Japan. In: Journal of gastroenterology. 2015 ; Vol. 50, No. 7. pp. 769-775.
@article{e72194a3bb2e4ed5875a6ecd59a6d9e7,
title = "Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan",
abstract = "Background: Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. In Western countries, streptozocin (STZ) has been established as a first-line anticancer drug for unresectable NET; however, STZ cannot be used in daily practice in Japan. The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. Methods: A retrospective multi-center survey was conducted. Five institutions with experience performing STZ chemotherapy participated in the study. The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. Results: Fifty-four patients were enrolled. The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. STZ monotherapy was used in one-fourth of the patients. The median progression-free and overall survival periods were 11.8 and 38.7 months, respectively, and sustained stable disease was obtained in some selected patients. The adverse events profile was mild and tolerable. Conclusions: Our survey showed the clinical benefit and safety of STZ therapy for Japanese patients with unresectable NET. Therefore, we recommend that STZ, which is the only cytotoxic agent available against NET, should be used in daily practice in Japan.",
author = "Taku Aoki and Norihiro Kokudo and Izumi Komoto and Kyoichi Takaori and Wataru Kimura and Keiji Sano and Takeshi Takamoto and Takuya Hashimoto and Takuji Okusaka and Chigusa Morizane and Tetsuhide Ito and Masayuki Imamura",
year = "2015",
month = "10",
day = "28",
doi = "10.1007/s00535-014-1006-3",
language = "English",
volume = "50",
pages = "769--775",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "7",

}

TY - JOUR

T1 - Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors

T2 - an analysis of a multi-center survey in Japan

AU - Aoki, Taku

AU - Kokudo, Norihiro

AU - Komoto, Izumi

AU - Takaori, Kyoichi

AU - Kimura, Wataru

AU - Sano, Keiji

AU - Takamoto, Takeshi

AU - Hashimoto, Takuya

AU - Okusaka, Takuji

AU - Morizane, Chigusa

AU - Ito, Tetsuhide

AU - Imamura, Masayuki

PY - 2015/10/28

Y1 - 2015/10/28

N2 - Background: Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. In Western countries, streptozocin (STZ) has been established as a first-line anticancer drug for unresectable NET; however, STZ cannot be used in daily practice in Japan. The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. Methods: A retrospective multi-center survey was conducted. Five institutions with experience performing STZ chemotherapy participated in the study. The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. Results: Fifty-four patients were enrolled. The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. STZ monotherapy was used in one-fourth of the patients. The median progression-free and overall survival periods were 11.8 and 38.7 months, respectively, and sustained stable disease was obtained in some selected patients. The adverse events profile was mild and tolerable. Conclusions: Our survey showed the clinical benefit and safety of STZ therapy for Japanese patients with unresectable NET. Therefore, we recommend that STZ, which is the only cytotoxic agent available against NET, should be used in daily practice in Japan.

AB - Background: Neuroendocrine tumors (NETs) are believed to be relatively rare and to follow a generally indolent course. However, liver metastases are common in NET patients and the outcome of NET liver metastasis is poor. In Western countries, streptozocin (STZ) has been established as a first-line anticancer drug for unresectable NET; however, STZ cannot be used in daily practice in Japan. The aim of the present study was to determine the status of STZ usage in Japan and to evaluate the effectiveness and safety of STZ chemotherapy in Japanese NET patients. Methods: A retrospective multi-center survey was conducted. Five institutions with experience performing STZ chemotherapy participated in the study. The patient demographics, tumor characteristics, context of STZ chemotherapy, and patient outcome were collected and assessed. Results: Fifty-four patients were enrolled. The main recipients of STZ chemotherapy were middle-aged patients with pancreatic NET and unresectable liver metastases. The predominant regimen was the weekly/bi-weekly intravenous administration of STZ combined with other oral anticancer agents. STZ monotherapy was used in one-fourth of the patients. The median progression-free and overall survival periods were 11.8 and 38.7 months, respectively, and sustained stable disease was obtained in some selected patients. The adverse events profile was mild and tolerable. Conclusions: Our survey showed the clinical benefit and safety of STZ therapy for Japanese patients with unresectable NET. Therefore, we recommend that STZ, which is the only cytotoxic agent available against NET, should be used in daily practice in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84937252269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937252269&partnerID=8YFLogxK

U2 - 10.1007/s00535-014-1006-3

DO - 10.1007/s00535-014-1006-3

M3 - Article

C2 - 25348496

AN - SCOPUS:84937252269

VL - 50

SP - 769

EP - 775

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 7

ER -